Taylor Frigon Capital Management LLC Has $2.26 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Taylor Frigon Capital Management LLC lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,060 shares of the medical device company’s stock after selling 3,494 shares during the period. Taylor Frigon Capital Management LLC’s holdings in DexCom were worth $2,260,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in shares of DexCom by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock worth $664,056,000 after buying an additional 214,136 shares in the last quarter. Jennison Associates LLC raised its stake in DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock worth $594,455,000 after acquiring an additional 710,858 shares in the last quarter. Groupama Asset Managment raised its stake in DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company’s stock worth $1,912,000 after acquiring an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of DexCom by 11.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock valued at $183,298,000 after purchasing an additional 288,381 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM opened at $89.91 on Thursday. The company has a fifty day moving average price of $84.29 and a two-hundred day moving average price of $76.47. The firm has a market capitalization of $35.13 billion, a PE ratio of 62.87, a P/E/G ratio of 2.30 and a beta of 1.14. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,083 shares of company stock valued at $3,309,794 in the last 90 days. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

DXCM has been the subject of a number of recent analyst reports. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a report on Thursday, January 16th. Citigroup raised their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.